Omeros Corporation maintaining a Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for MASP-3 inhibitor zaltenibart. OMER's zaltenibart targets Paroxysmal Nocturnal ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

“This is not about making it easier to become a lawyer,” Utah Supreme Court Associate Chief Justice, and Working Group Chair, John A. Pearce, said in a statement. “It’s about making it smarter.” Utah ...

The objective of this study was to evaluate the methodology to establish the hemolytic activity of alternative complement pathway as an indicator of the innate immunity in Brazilian fish pacu ...

Lots of people are excited about the idea of using plants to help us draw down some of the excess carbon dioxide we’ve been pumping into the atmosphere. It would be nice to think that we could ...

LONE TREE, Colo. — As fewer people go to school to be teachers and many leave the profession altogether, school districts are turning to alternative pathways to bring new teachers into classrooms. "I ...

Texas will become the 13th state to offer an alternative licensure pathway for experienced international physicians this September, The Dallas Morning News reported Aug. 13. House Bill 2038 — called ...

Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...

Elon Musk, who has revolutionized the auto industry, launched rockets into space and built a global business empire may now be facing his most daunting challenge yet: shaking up the two-party system ...

ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...